Your browser doesn't support javascript.
loading
Rapid clearing CT-001 restored hemostasis in mice with coagulopathy induced by activated protein C.
Sim, Derek S; Mallari, Cornell R; Bauzon, Maxine; Hermiston, Terry W.
Affiliation
  • Sim DS; From the Research Department (D.S.S., C.R.M., T.W.H.), Coagulant Therapeutics Corporation; and Consultant of Coagulant Therapeutics Corporation (M.B.), Berkeley, California.
J Trauma Acute Care Surg ; 96(2): 276-286, 2024 Feb 01.
Article in En | MEDLINE | ID: mdl-37335129
ABSTRACT

BACKGROUND:

Activated protein C (APC) is one of the mechanisms contributing to coagulopathy, which is associated with high mortality. The counteraction of the APC pathway could help ameliorate bleeding. However, patients also transform frequently from a hemorrhagic state to a prothrombotic state at a later time. Therefore, a prohemostatic therapeutic intervention should take this thrombotic risk into consideration.

OBJECTIVES:

CT-001 is a novel factor VIIa (FVIIa) with enhanced activity and desialylated N-glycans for rapid clearance. We assessed CT-001 clearance in multiple species and its ability to reverse APC-mediated coagulopathic blood loss.

METHODS:

The N-glycans on CT-001 were characterized by liquid chromatography-mass spectrometry. Three species were used to evaluate the pharmacokinetics of the molecule. The potency and efficacy of CT-001 under APC pathway-induced coagulopathic conditions were assessed by coagulation assays and bleeding models.

RESULTS:

The N-glycosylation sites of CT-001 had high occupancy of desialylated N-glycans. CT-001 exhibited 5 to 16 times higher plasma clearance in human tissue factor knockin mice, rats, and cynomolgus monkeys than wildtype FVIIa. CT-001 corrected the activated partial thromboplastin time and thrombin generation of coagulopathic plasma to normal in in vitro studies. In an APC-mediated saphenous vein bleeding model, 3 mg/kg of CT-001 reduced bleeding time in comparison with wildtype FVIIa. The correction of bleeding by CT-001 was also observed in a coagulopathic tail amputation severe hemorrhage mouse model. The efficacy of CT-001 is independent of the presence of tranexamic acid, and the combination of CT-001 and tranexamic acid does not lead to increased thrombogenicity.

CONCLUSION:

CT-001 corrected APC pathway-mediated coagulopathic conditions in preclinical studies and could be a potentially safe and effective procoagulant agent for addressing APC-mediated bleeding.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tranexamic Acid / Blood Coagulation Disorders Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: J Trauma Acute Care Surg Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tranexamic Acid / Blood Coagulation Disorders Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: J Trauma Acute Care Surg Year: 2024 Document type: Article